Trials / Completed
CompletedNCT00261404
TNFerade™ Biologic Plus Radiation for Metastatic Melanoma
A Phase II, Open Label, Single Arm, "Proof of Concept" Study of TNFerade™ Plus Radiation in Patients With Metastatic Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- GenVec · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II, open label study in which patients with metastatic melanoma (stage III or IV) who have cancer which is not considered curable by surgery will receive intratumoral injections of TNFerade™ plus radiation as a 4-week treatment, followed by a 3 year follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TNFerade™ |
Timeline
- First posted
- 2005-12-05
- Last updated
- 2011-05-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00261404. Inclusion in this directory is not an endorsement.